News, reviews and podcasts from annual scientific meetings and symposiums around the world.
Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma…
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response…
A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage…
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy…
Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab was safe and…
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK NSCLC).…
The incidence of early onset colorectal cancer has increased nearly 50 percent in the last…
Analysing fragments of DNA that are shed by tumours into the bloodstream, could indicate early…
“Living with the uncertainty of whether cancer will develop is very difficult, so it’s exciting…